NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis $4.49 +0.03 (+0.67%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.40▼$4.6750-Day Range$4.33▼$8.6452-Week Range$4.23▼$15.80Volume22,461 shsAverage Volume43,973 shsMarket Capitalization$28.83 millionP/E RatioN/ADividend YieldN/APrice Target$130.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Clene alerts: Email Address Clene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,795.3% Upside$130.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingSelling Shares$5,460 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.80) to ($6.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 starsMedical Sector526th out of 936 stocksPharmaceutical Preparations Industry240th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClene has only been the subject of 2 research reports in the past 90 days.Read more about Clene's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.46% of the float of Clene has been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently increased by 34.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 1.8 News and Social Media Coverage News SentimentClene has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Clene this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,460.00 in company stock.Percentage Held by Insiders25.10% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.28% of the stock of Clene is held by institutions.Read more about Clene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($6.80) to ($6.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Clene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Clene Stock (NASDAQ:CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More CLNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLNN Stock News HeadlinesJuly 25 at 6:50 PM | benzinga.comClene (NASDAQ:CLNN) Stock Quotes, Forecast and News SummaryJuly 19, 2024 | markets.businessinsider.comOptimistic Outlook on Clene’s CNM-Au8 for ALS Amid Anticipated Regulatory MilestonesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 12, 2024 | globenewswire.comClene to Present at the Emerging Growth ConferenceJuly 11, 2024 | globenewswire.comClene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALSJuly 9, 2024 | globenewswire.comClene Announces 1-for-20 Reverse Stock SplitJune 24, 2024 | globenewswire.comClene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual ConferenceJune 21, 2024 | globenewswire.comClene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett SyndromeJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 18, 2024 | globenewswire.comClene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS MeetingMay 28, 2024 | globenewswire.comClene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)May 24, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative DiseasesMay 23, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For CleneMay 14, 2024 | finance.yahoo.comClene to Present at Upcoming May ConferencesMay 14, 2024 | globenewswire.comClene to Present at Upcoming May ConferencesMay 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)May 10, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation HighlightsMay 9, 2024 | finance.yahoo.comClene First Quarter 2024 Earnings: Misses ExpectationsSee More Headlines Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$130.00 High Stock Price Target$200.00 Low Stock Price Target$80.00 Potential Upside/Downside+2,795.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($9.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,500,000.00 Net Margins-7,873.23% Pretax Margin-7,873.23% Return on Equity-224.28% Return on Assets-60.21% Debt Debt-to-Equity Ratio1.66 Current Ratio1.23 Quick Ratio1.22 Sales & Book Value Annual Sales$620,000.00 Price / Sales46.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book2.15Miscellaneous Outstanding Shares6,422,000Free Float4,810,000Market Cap$28.83 million OptionableOptionable Beta0.46 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Robert Etherington MBA (Age 57)CEO, President & Director Comp: $1.06MMr. Morgan R. Brown CPA (Age 56)M.B.A., Chief Financial Officer Comp: $584.88kMr. Mark G. Mortenson ESQ. (Age 66)Chief Science Officer Comp: $729.92kMr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryMr. Michael T. HotchkinChief Development OfficerMs. Mary Anne McneilHead of Human ResourcesDr. Benjamin M. Greenberg M.D.M.H.S., Head of MedicalMore ExecutivesKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOKaryopharm TherapeuticsNASDAQ:KPTIAdageneNASDAQ:ADAGJourney MedicalNASDAQ:DERMCyteir TherapeuticsNASDAQ:CYTTView All CompetitorsInsiders & InstitutionsCsenge Advisory GroupBought 153,000 shares on 7/10/2024Ownership: 0.210%CVI Holdings LLCSold 111,200 shares on 5/7/2024Ownership: 0.000%General Resonance LlcSold 650 sharesTotal: $5,460.00 ($8.40/share)General Resonance LlcSold 500 sharesTotal: $3,300.00 ($6.60/share)General Resonance LlcSold 1,125 sharesTotal: $8,775.00 ($7.80/share)View All Insider TransactionsView All Institutional Transactions CLNN Stock Analysis - Frequently Asked Questions How have CLNN shares performed this year? Clene's stock was trading at $5.9320 at the beginning of the year. Since then, CLNN shares have decreased by 24.3% and is now trading at $4.49. View the best growth stocks for 2024 here. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) released its earnings results on Wednesday, May, 8th. The company reported ($1.80) EPS for the quarter, hitting the consensus estimate of ($1.80). The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. Clene had a negative trailing twelve-month return on equity of 224.28% and a negative net margin of 7,873.23%. When did Clene's stock split? Shares of Clene reverse split on Thursday, July 11th 2024. The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Clene's major shareholders? Clene's top institutional investors include Csenge Advisory Group (0.21%). Insiders that own company stock include General Resonance Llc, David J Matlin, John Henry Stevens, Jonathon Gay, Alison Mosca, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLNN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
